Pacific Edge Limited (NZE:PEB)
New Zealand
· Delayed Price · Currency is NZD | Market Cap | 175.89M |
| Revenue (ttm) | 18.24M |
| Net Income (ttm) | -34.55M |
| Shares Out | 1.02B |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 228,819 |
| Average Volume | 387,726 |
| Open | 0.170 |
| Previous Close | 0.172 |
| Day's Range | 0.170 - 0.176 |
| 52-Week Range | 0.078 - 0.305 |
| Beta | 0.80 |
| RSI | 42.77 |
| Earnings Date | May 25, 2026 |
About Pacific Edge
Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have a low probability of bladder cancer; and Cxbladder Monitor, a non-inva... [Read more]
Financial Performance
In fiscal year 2025, Pacific Edge's revenue was 22.75 million, a decrease of -9.83% compared to the previous year's 25.23 million. Losses were -29.94 million, 1.36% more than in 2024.
Financial StatementsNews
Pacific Edge Earnings Call Transcript: H1 2026
Revenue and test volumes declined sharply due to Medicare non-coverage, resulting in a $19.1M net loss and increased reliance on cash reserves. Strategic milestones include a price increase for Triage Plus and a key policy review by Novitas in early 2026, with recovery dependent on appeal outcomes.
Pacific Edge Transcript: AGM 2025
The meeting highlighted strategic progress with AUA guideline inclusion and a successful capital raise, despite the significant challenge of losing Medicare coverage. The board emphasized governance, risk management, and a pivot to commercial payers, with all resolutions passed by strong shareholder support.
Pacific Edge Earnings Call Transcript: H2 2025
Test volumes and revenue declined year-over-year, but commercial payer mix and sales efficiency improved. Major clinical guideline inclusion and a capital raise position the business for future growth, with Medicare coverage reinstatement a key catalyst.
Pacific Edge Earnings Call Transcript: H1 2025
Operating revenue rose 1.4% half-on-half but fell 16.3% year-over-year, with net loss steady at NZD 14.5 million and cash reserves at NZD 35.9 million. Strategic focus is on Triage Plus launch, Medicare coverage, and expanding APAC presence.
Pacific Edge Transcript: AGM 2024
The meeting reviewed strong revenue growth and operational resilience despite Medicare uncertainty, highlighted strategic focus on U.S. and Asia-Pacific markets, and discussed new product launches and digital initiatives. Shareholders supported all resolutions, and leadership addressed key risks and future plans.